These findings suggest that the AFP-HSP90-Myc/Met axis may contribute to chemoresistance in HCC, and targeting this axis, either through AFP knockdown or HSP90 inhibition, could enhance the effectiveness of sorafenib and cisplatin in treating AFP-producing HCC and gastric cancer, respectively. The gene discussed is HSP90AA1; the disease is hepatocellular carcinoma.